OBJ LimitedInvestor SeminarMagnetic micro-array drug delivery...

Column 1

0

OBJ LimitedInvestor Seminar​ Magnetic micro-array drug delivery and product enhancement technologies Partnered with the world leading companies, Procter & Gamble and Coty Inc. When: Tuesday 24th May 2016 5:30-7:00pmWhere: Baker Young Stockbrokers Seminar RoomLevel 6, 121 King William Street, AdelaideRSVP: [email protected] or 08 8236 8866​ We are pleased to extend this invitation for you to attend an Investor Seminar from OBJ Limited ("OBJ" or "the Company") (ASX: OBJ) given by Jeff Edwards (Managing Director) and Glynn Dennison (Chairman). OBJ Limited is an Australian life sciences company that has developed various proprietary magnetic micro-array drug delivery and product enhancement technologies for the pharmaceutical, healthcare, cosmetic, homecare and consumer goods sectors. The Company's technology has been developed over 15 years and is proven by independent studies & validated by collaboration and now partnering agreements with some of the world's major pharmaceutical and consumer goods companies. OBJ has partnered/collaborated with the world's leading companies, Procter & Gamble (P&G), GlaxoSmithKline (GSK) & Coty to develop and bring to market next generation products that deliver products transdermally, using physical science rather than chemistry to provide new levels of product performance. As OBJ's technology improves the effectiveness and efficiency of existingformulations/ingredients of products already in the market the regulatory pathway is greatly reduced and thus the time to market should likewise be significantly shorter. After extensive development and numerous trials, OBJ is now establishing itself as the selected technology partner for enhanced delivery and product performance to an increasing number of major international corporations in both the pharmaceutical and consumer healthcare fields. On the back of a very successful soft launch, the SK-II Eye Wand has now been dispatched for a global launch across the SK-II range and another globally recognized skin care brand. We see this as being the platform for the company to launch further products and grow its royalty revenues. The future for OBJ is looking very promising for shareholders, being on the verge of a number of global product licensing agreements coupled with a deep, late stage development pipeline. As places are strictly limited please advise us of your attendance ASAP by contacting: Alastair Murray - 08 8236 8866 or [email protected] We hope you can join us. The Team at Baker Young.